Early detection of postpartum haemorrhage and treatment using the World Health Organization MOTIVE ‘first response’ bundle:
early detection
massage of Uterus
oxytocin Drugs
tranexamic acid
IV fluids
Examination and Escalation
Early detection of postpartum haemorrhage and treatment using the World Health Organization MOTIVE ‘first response’ bundle:
early detection
massage of Uterus
oxytocin Drugs
tranexamic acid
IV fluids
Examination and Escalation
210,132 women undergoing vaginal birth
The E-MOTIVE trial showed early detection & treatment of PPH is highly effective
Delivering a 1.8x increase in PPH detection 60% decrease in the composite primary outcome (severe PPH, laparotomies or deaths from bleeding)
Once fully implemented
this difference could equate to:
20,000 fewer deaths per year OR
1 life saved every 24 minutes
80 hospitals
across four Low- and Middle-income Countries
David Sackett Annual Trial of the Year Award
E-MOTIVE wins prestigious Trial of the Year Award
The landmark E-MOTIVE study, led by University of Birmingham researchers and coordinated by the Birmingham Clinical Trials Unit, tested a package of low-cost interventions that resulted in a 60% reduction in heavy bleeding following childbirth.
David Sackett Annual Trial of the Year Award
E-MOTIVE wins prestigious Trial of the Year Award
The landmark E-MOTIVE study, led by University of Birmingham researchers and coordinated by the Birmingham Clinical Trials Unit, tested a package of low-cost interventions that resulted in a 60% reduction in heavy bleeding following childbirth.
E-MOTIVE Impact.
Since the publication of the trial results in May 2023, the E-MOTIVE trial has had rapid uptake and impact…
- Updated WHO guidelines for PPH
- Development of new national guidelines in Pakistan, with other countries following suit
- Commitment to invest over 500,000,000 USD for implementation across 20 countries with the highest PPH burden
- Global media coverage, including being showcased at Davos by Bill Gates and within the ‘Gates Goalkeepers’ campaign
- Peer recognition including as one of NEJM’s ‘Most Notable Articles’ of 2023
E-MOTIVE Impact.
Since the publication of the trial results in May 2023, the E-MOTIVE trial has had rapid uptake and impact…
- Updated WHO guidelines for PPH
- Development of new national guidelines in Pakistan, with other countries following suit
- Commitment to invest over 500,000,000 USD for implementation across 20 countries with the highest PPH burden
- Global media coverage, including being showcased at Davos by Bill Gates and within the ‘Gates Goalkeepers’ campaign
- Peer recognition including as one of NEJM’s ‘Most Notable Articles’ of 2023
